Barta JA, Powell CA, Wisnivesky JP, Glob A, Author H. Global Epidemiology of Lung Cancer HHS Public Access Author manuscript. Ann Glob Heal. 2019;85(1) [cited 2020 Feb 25]. Available from: http://creativecommons.org/licenses/by/4.0/.
Zhang C, Leighl NB, Wu Y-L, Zhong W-Z. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019;12(1):45 [cited 2020 Feb 25]. Available from: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0731-8.
Article
Google Scholar
Andersson S, Ilonen I, Järvinen T, Rauma V, Räsänen J, Salo J. Surgically Treated Unsuspected N2-Positive NSCLC: Role of Extent and Location of Lymph Node Metastasis. Clin Lung Cancer. 2018;19(5):418–25 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29880414.
Article
Google Scholar
Chen F, Wang X-Y, Han X-H, Wang H, Qi J. Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease. Int J Clin Exp Med. 2015;8(7):11295–300 [cited 2020 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26379938.
PubMed
PubMed Central
Google Scholar
McDonald F, De Waele M, Hendriks LEL, Faivre-Finn C, Dingemans A-MC, Van Schil PE. Management of stage I and II nonsmall cell lung cancer. Eur Respir J. 2017;49(1) [cited 2020 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28049169.
Aktas GE, Karamustafaoğlu YA, Balta C, Süt N, Sarikaya İ, Sarikaya A. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer. Nucl Med Commun. 2018;39(11):995–1004 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30188416.
Article
Google Scholar
Gómez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M, Gimferrer JM, et al. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. Eur J Cardiothorac Surg. 2010;37(5):1168–1174 [cited 2020 May 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20116273.
D'Andrilli A, Maurizi G, Venuta F, Rendina EA. Mediastinal staging: when and how? Gen Thorac Cardiovasc Surg. 2020;68(7):725–32. https://doi.org/10.1007/s11748-019-01263-8.
Article
PubMed
Google Scholar
Turner SR, Seyednejad N, Nasir BS. Patterns of Practice in Mediastinal Lymph Node Staging for Non-Small Cell Lung Cancer in Canada. Ann Thorac Surg. 2018;106(2):428–34 [cited 2020 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29596820.
Article
Google Scholar
Cho HJ, Kim SR, Kim HR, Han J-O, Kim Y-H, Kim DK, et al. Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer. Ann Thorac Surg. 2014;97(6):1920–5 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24768044.
Article
Google Scholar
Yang-Chun F, Min F, Di Z, Yan-Chun H. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People’s Republic of China. Medicine (Baltimore). 2016;95(18):e3568 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27149479.
Article
Google Scholar
Yu H, Huang X, Zhu Z, Hu Y, Ou W, Zhang L, et al. Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma. Chin J Cancer Res [Internet]. 2014;26(1):89–94 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24653630.
Molina R, Marrades RM, Augé JM, Escudero JM, Viñolas N, Reguart N, Ramirez J, Filella X, Molins L, Agustí A. Assessment of a combined panel of six Serum tumor markers for Lung Cancer. Am J Respir Crit Care Med. 2016;193(4):427–37. https://doi.org/10.1164/rccm.201404-0603OC.
Article
CAS
PubMed
Google Scholar
Decaluwé H, Dooms C, D’Journo XB, Call S, Sanchez D, Haager B, et al. Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study. Eur Respir J. 2017;50(6) [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29269579.
Hishida T, Yoshida J, Nishimura M, Nishiwaki Y, Nagai K. Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer. Thorax. 2008;63(6):526–31 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18024539.
Article
CAS
Google Scholar
Toloza EM, Harpole L, DC MC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123(1 Suppl):137S–46S [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12527573.
Article
Google Scholar
Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest. 2006;130(6):1791–5 [cited 2020 May 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17166998.
Article
Google Scholar
Buccheri G, Ferrigno D. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test. Ann Thorac Surg. 2003;75(3):973–80 [cited 2020 Feb 28]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0003497502046386.
Article
Google Scholar
Reinmuth N, Brandt B, Semik M, Kunze W-P, Achatzy R, Scheld HH, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 2002;36(3):265–70 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12009236.
Article
Google Scholar
Suzuki K, Nagai K, Yoshida J, Moriyama E, Nishimura M, Takahashi K, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg [Internet]. 1999;67(4):927–932 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10320230.
Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011;74(1):112–7 [cited 2020 May 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21397974.
Article
Google Scholar
Hsu W-H, Huang C-S, Hsu H-S, Huang W-J, Lee H-C, Huang B-S, et al. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer. Ann Thorac Surg. 2007;83(2):419–24 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17257963.
Article
Google Scholar
Concannon JP, Dalbow MH, Hodgson SE, Headings JJ, Markopoulos E, Mitchell J, et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma. Cancer. 1978;42(S3):1477–83 [cited 2020 May 30]. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/10970142(197809)42:3+%3C1477::AID-CNCR2820420818%3E3.0.CO;2-E.
Article
CAS
Google Scholar
Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué I, Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Datab Syst Rev. 2014;2014(11):CD009519 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25393718.
Google Scholar
Kuo Y-S, Zheng M-Y, Huang M-F, Miao C-C, Yang L-H, Huang T-W, et al. Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression. Sci Rep [Internet]. 2020;10(1):2066 [cited 2020 May 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32034239.
Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, Asada H, et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non- small cell lung cancer. Ann Thorac Surg. 2002;74(1):174–9 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12118753.
Article
Google Scholar
Wang J, Ma Y, Zhu Z-H, Situ D-R, Hu Y, Rong T-H. Expression and prognostic relevance of tumor carcinoembryonic antigen in stage IB non-small cell lung cancer. J Thorac Dis. 2012;4(5):490–6 [cited 2020 may 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23050113.
CAS
PubMed
PubMed Central
Google Scholar
Nisselbaum JS, Smith CA, Schwartz D, Schwartz MK. Comparison of Roche RIA, Roche EIA, Hybritech EIA, and Abbott EIA methods for measuring carcinoembryonic antigen. ClinChem. 1988;34(4):761–4 Available from: https://doi.org/10.1093/clinchem/34.4.761.
CAS
Google Scholar
Maeda R, Suda T, Hachimaru A, Tochii D, Tochii S, Takagi Y. Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer. J Thorac Dis. 2017;9(1):176–86. https://doi.org/10.21037/jtd.2017.01.30.
Article
PubMed
PubMed Central
Google Scholar
Takahashi Y, Horio H, Sakaguchi K, Hiramatsu K, Kawakita M. Significant correlation between urinary N1, N12-diacetylspermine and tumor invasiveness in patients with clinical stage IA non-small cell lung cancer. BMC Cancer. 2015;15(1):65 [cited 2020 Feb 28]. Available from: http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1068-5.
Article
Google Scholar
Kawachi R, Nakazato Y, Takei H, Koshi-ishi Y, Goya T. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage? Interact Cardiovasc Thorac Surg. 2009;9(2):199–202 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19457896.
Article
Google Scholar
Cho S, Song IH, Yang HC, Kim K, Jheon S. Predictive Factors for Node Metastasis in Patients With Clinical Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg. 2013;96(1):239–45 [cited 2020 Feb 28]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0003497513006309.
Article
Google Scholar
Kaseda K, Asakura K, Kazama A, Ozawa Y. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. World J Surg. 2016;40(12):2976–83 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27456499.
Article
Google Scholar
Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, et al. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: Differences according to histology and smoking status. J Surg Oncol. 2013;107(6):619–24 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23192365.
Article
CAS
Google Scholar
Koike T, Koike T, Yamato Y, Yoshiya K, Toyabe S-I. Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients. J Thorac Oncol. 2012;7(8):1246–51 [cited 2020 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22659962.
Article
Google Scholar
Komatsu H, Mizuguchi S, Izumi N, Chung K, Hanada S, Inoue H, et al. Sialyl Lewis X as a predictor of skip N2 metastasis in clinical stage IA non-small cell lung cancer. World J SurgOncol. 2013;11:309 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24313932.
Google Scholar
Tsutani Y, Murakami S, Miyata Y, Nakayama H, Yoshimura M, Okada M. Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung. Eur J Cardio-Thoracic Surg. 2015;47(6):1022–6 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25293403.
Article
Google Scholar
Ye B, Cheng M, Li W, Ge X-X, Geng J-F, Feng J, et al. Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg. 2014;98(1):217–23 [cited 2020 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24841547.
Article
Google Scholar